Literature DB >> 19772824

Tocilizumab versus methotrexate in moderate to severe rheumatoid arthritis.

Aarat M Patel1, Larry W Moreland.   

Abstract

Entities:  

Year:  2009        PMID： 19772824      PMCID： PMC3741095          DOI： 10.1007/s11926-009-0057-6

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  2 in total

Review 1.  Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.

Authors:  Katrina E Donahue; Gerald Gartlehner; Daniel E Jonas; Linda J Lux; Patricia Thieda; Beth L Jonas; Richard A Hansen; Laura C Morgan; Kathleen N Lohr
Journal:  Ann Intern Med       Date:  2007-11-19       Impact factor: 25.391

2.  IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial.

Authors:  P Emery; E Keystone; H P Tony; A Cantagrel; R van Vollenhoven; A Sanchez; E Alecock; J Lee; J Kremer
Journal:  Ann Rheum Dis       Date:  2008-07-14       Impact factor: 19.103
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.